Johns Hopkins Center for Psychedelic and Consciousness Research ’s Post

AJEM Volume 4, Issue 2, Now Live! Experts tout the immense potential of psychedelic therapy, but also paint a cautionary tale of careful patient selection and treatment that is guided by a mental health professional. Duzan et al. explores the chemical composition and pharmacologic characteristics of cannabis extracts on glioblastoma cell lines. In a large retrospective study, Vaillancourt et al. examine physician-guided medical cannabis treatment for comorbid anxiety and depression disorders in Canadian multidisciplinary clinics. Fisher R. discusses how rescheduling cannabis would be a game changer for the industry. https://lnkd.in/eHiq-neW Leslie Apgar, Ken Watkins, Meg Block Roloff, MPH, Karla Bur, Tracie Palmer, David Puccio, Ashraf Duzan, Aaliyah Caupain,Aleksi Hupli, PhD, Riley D. Kirk, PhD, Paloma Lehfeldt, MD, MA, Miyabe Shields, PhD, Waldemar Debinski

📢Announcing the latest issue of the American Journal of Endocannabinoid Medicine - AJEM Volume 4, Issue 2.📗 🥳🎉 🌿Experts tout the immense potential of psychedelic therapy, but also paint a cautionary tale of careful patient selection and treatment that is guided by a mental health professional. ⚕️⚠️ 🌿Duzan et al. explores the chemical composition and pharmacologic characteristics of cannabis extracts on glioblastoma cell lines. 🧠🌿 🌿In a large retrospective study, Vaillancourt et al. examine physician-guided medical cannabis treatment for comorbid anxiety and depression disorders in Canadian multidisciplinary clinics. 😰🥺 🌿Fisher R. discusses how rescheduling cannabis would be a game changer for the industry. ⚖️🌿 🌿and more! To read the latest issue, go to 👉 https://lnkd.in/eHiq-neW Leslie Apgar, Ken Watkins, Meg Block Roloff, MPH, Karla Bur, Tracie Palmer, David Puccio, Ashraf Duzan, Aaliyah Caupain, Aleksi Hupli, PhD, Riley D. Kirk, PhD, Paloma Lehfeldt, MD, MA, Miyabe Shields, PhD, Waldemar Debinski Haymarket Media US Haymarket Media Group Haymarket Medical Education #HaymarketAJEM_Consultant #AJEM #endocannabinoidmedicine #medicalcannabis #CBD #THC #CBG #terpenes #psychedelictherapy #patientcare #patientsafety #glioblastoma #braincancer #braincancerawareness #braintumor #anxiety #anxietytreatment #anxietyrelief #depression #depressionawareness #depressionsupport #depressiontreatment #medicalcannabisdoctors #mmjdrs #cannabinoidspecialists #cannabislegalization #ControlledSubstanceAct #cannabisrescheduling #cannabisdescheduling #cannabisadvocacy

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California Dozens of new studies involving Schedule I and II substances—many of which employ psychedelics—are unable to commence in California, despite having clearance from the FDA, DEA and Institutional Review Boards. The cause of the hold-up? An obscure—yet apparently mandatory—checkpoint in the path to study initiation: the Research Advisory Panel of California (RAP-C). California is simultaneously the state with the most clinical trials in the U.S., representing over a quarter of registered trials in the country, while also being the only state to feature such a panel, which may be becoming its Achilles’ heel. Here, look at what RAP-C is, how it operates, its current impasse, and potential paths forward. https://lnkd.in/eRZQ4whd

Published in "Experimental and Clinical Psychopharmacology," this study fills a significant gap in the existing literature by assessing the potential of CBD to mitigate the often debilitating symptoms associated with menstruation. This topic has not been extensively explored until now. The research adopts a methodologically rigorous pre-post, randomized, open-label trial design to evaluate the impacts of oral CBD isolate on MRS. With participants assigned to two distinct dosing groups and followed over a period extending beyond the initial baseline assessment through three months of CBD consumption, the study meticulously documents the changes in MRS and related psychological outcomes. #GCRC #Research #Endocannabinoids #Cannabinoids https://lnkd.in/g9BTv27w

Interesting Medscape article discussing the potential for the reclassification of psilocybin by the DEA, worth the 5-10 min read :)

10/12/2021: "A team of dozens of high-level cannabinoid medicine scientists and scholars from Brazil and Israel led by famed Professor Raphael Mechoulam recruited 321 patients from Emergency Rooms to gain the most accurate data possible. The virus-positive patients have participated in a randomized, double-blind, placebo-controlled trial to determine truly how effective the cannabinoid could treat those with mild to moderate symptoms." https://lnkd.in/gxGE-Mut

We must rethink a lot of older theories about disease and make sure we scrutinize all past publications to make sure it is not just propaganda and Pharma indoctrination. Sad state of affairs for “high power medical journals”. This may be their downfall for hopping in bed with the pharmaceutical industry (biomedical-industrial-complex). We are also seeing this in other sectors such as the mainstream media, captured government agencies tasked with protecting the public and much more. Proud to support the new Journal of the FLCCC and also other independent new journals like the Journal of the BODY and others. These new journals will bring back integrity and truth to scientific journals. https://lnkd.in/eSEzPGvM

Over the 5 years I spent in the psychedelic space, I developed an incredible amount of respect for all the people working hard to advance access and acceptance of these medicines, including some mentioned in this article. So please take the following with the respect, love and sincerity with which it is given. Trying to distance yourself from the work of Rick Doblin and the folks at Multidisciplinary Association for Psychedelic Studies (MAPS) when the chips are down is, in the words of Kid President, "not cool, Robert Frost". Both atai Life Sciences and Compass Pathways owe their entire existence to the work of Rick and Amanda Feilding. And simply because an antiquated, uptight advisory committee at the FDA said little more than "you didn't play by our rules so we are going to vote against you", when anyone who is paying attention knows that the right answer is to approve MDMA-assisted therapy (see your latest post on LinkedIn, Christian Angermayer if there is any doubt), is just classless imho. In the words of Tom Robbins, sometimes you have to separate what is right from what is merely legal. And what is right here is to join the chorus of all those people in the community and the industry who are saying "that's bullshit!", and doing your best to convince the FDA to come to the right answer despite what a foolish advisory committee voted. If not for the millions of people suffering trauma without any viable treatment options, if not because the current drug laws are incomprehensibly dumb, if not out of simple respect for those who dedicated their lives to making your business possible, then simply because, at a basic level of dignity, it's the right thing to do. If you want to change the world, change yourselves. And if you can't do that, then try to change the system that's working against the world. Start now.

We must rethink a lot of older theories about disease and make sure we scrutinize all past publications to make sure it is not just propaganda and Pharma indoctrination. Sad state of affairs for “high power medical journals”. This may be their downfall for hopping in bed with the pharmaceutical industry (biomedical-industrial-complex). We are also seeing this in other sectors such as the mainstream media, captured government agencies tasked with protecting the public and much more. Proud to support the new Journal of the FLCCC and also other independent new journals like the Journal of the BODY and others. These new journals will bring back integrity and truth to scientific journals. https://lnkd.in/eFkHS4e7

Notably, the research delineates the dual role of the ECS in promoting neuronal synchronization and regulating gamma oscillations, which are vital to processing olfactory stimuli. These findings help better understand the ECS as a multifaceted modulator of brain function and beyond, influencing sensory perception and potentially other cognitive and physiological processes. The study's implications extend to the potential therapeutic exploitation of ECS targeting to modulate sensory perception and address disorders related to ECS dysregulation, which is often noted as the number one reason people have sensitivities, intolerances, and tolerances to both exogenous and their own bodies' cannabinoids. #GCRC #ECS #Olfactory #Research https://lnkd.in/gnF2kXUZ